Your browser doesn't support javascript.
loading
Hypomethylating Agents (HMAs) as Salvage Therapy in Relapsed or Refractory AML: An Italian Multicentric Retrospective Study.
Lessi, Federica; Laurino, Marica; Papayannidis, Cristina; Vitagliano, Orsola; Grimaldi, Francesco; Lazzarotto, Davide; Gottardi, Michele; Crisà, Elena; Riva, Marta; Reda, Gianluigi; Ermani, Mario; Semenzato, Gianpietro; Trentin, Livio; Ferrara, Felicetto.
Afiliación
  • Lessi F; Hematology Unit, Department of Medicine (DIMED), Azienda Ospedale Università Padova, 35100 Padova, Italy.
  • Laurino M; Hematology Unit, Department of Medicine (DIMED), Azienda Ospedale Università Padova, 35100 Padova, Italy.
  • Papayannidis C; Department of Hematology and Oncology "L. and A. Seràgnoli" S.Orsola Malpighi University Hospital, 40100 Bologna, Italy.
  • Vitagliano O; Division of Hematology, Cardarelli Hospital, 80100 Naples, Italy.
  • Grimaldi F; Department of Medicina Clinica e Chirurgia, AOU Federico II di Napoli, 80100 Naples, Italy.
  • Lazzarotto D; Hematology and SCT Unit, University of Udine, Azienda Sanitaria Universitaria Integrata di Udine, 33100 Udine, Italy.
  • Gottardi M; Hematology, Treviso Hospital, 31100 Treviso, Italy.
  • Crisà E; Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale and Ospedale Maggiore della Carità, 28100 Novara, Italy.
  • Riva M; Hematology, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy.
  • Reda G; Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, 20162 Milano, Italy.
  • Ermani M; Statistic and Informatics Unit, Department of Neurosciences, School of Medicine, University of Padua, 35100 Padua, Italy.
  • Semenzato G; Hematology Unit, Department of Medicine (DIMED), Azienda Ospedale Università Padova, 35100 Padova, Italy.
  • Trentin L; Hematology Unit, Department of Medicine (DIMED), Azienda Ospedale Università Padova, 35100 Padova, Italy.
  • Ferrara F; Division of Hematology, Cardarelli Hospital, 80100 Naples, Italy.
Biomedicines ; 9(8)2021 Aug 06.
Article en En | MEDLINE | ID: mdl-34440176
Data on the use of azacytidine and decitabine as salvage therapy for acute myeloid leukemia are limited. We retrospectively reviewed clinical records of 100 patients treated with hypomethylating agents (HMA) as salvage therapy in nine Italian institutions. A total of 24% of patients obtained a response to HMA (CR, PR, or CRi), while 26% showed a stable disease (SD); 50% of patients experienced progressive disease. Median OS was 6.5 months. OS in patients with de novo AML was 6.1 months, while OS in patients with secondary AML (sAML) was 12.3 months (p = 0.037). Median OS after HMA in patients with SD as best response to HMA was similar to median OS in patients with response to HMA (10.6 months vs. 13 months). On multivariate analysis, OS difference between patients who obtained a response versus patients who did not was significant (p = 0.0037). OS difference in sAML was significantly better than in de novo AML (p < 0.00001). HMA showed a remarkable efficacy in terms of response rate and OS in a subgroup of patients (sAMLs), historically characterized by a poor outcome. Therefore, 5Azacitidine and decitabine may represent a good clinical option in a selected patient population with relapsed or refractory AML, unsuitable for allo-HSCT.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Observational_studies Idioma: En Revista: Biomedicines Año: 2021 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Observational_studies Idioma: En Revista: Biomedicines Año: 2021 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza